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Abstract
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimen-
tal and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be
anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether
treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis
in patients with non-alcoholic steatohepatitis (NASH).
Methods
Double-blind randomised-controlled trial of Losartan 50 mg once a day versus placebo for
96 weeks in patients with histological evidence of NASH. The primary outcome for the study
was change in histological fibrosis stage from pre-treatment to end-of-treatment.
Results
The study planned to recruit 214 patients. However, recruitment was slower than expected,
and after 45 patients were randomised (median age 55; 56% male; 60% diabetic; median
fibrosis stage 2), enrolment was suspended. Thirty-two patients (15 losartan and 17 pla-
cebo) completed follow up period: one patient (6.7%) treated with losartan and 4 patients
(23.5%) in the placebo group were “responders” (lower fibrosis stage at follow up compared
with baseline). The major reason for slow recruitment was that 39% of potentially eligible
patients were already taking an ARB or angiotensin converting enzyme inhibitor (ACEI), and
15% were taking other prohibited medications.
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Conclusions
Due to the widespread use of ACEI and ARB in patients with NASH this trial failed to recruit
sufficient patients to determine whether losartan has anti-fibrotic effects in the liver.
Trial registration
ISRCTN 57849521
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, which has
dramatically increased in prevalence due to the obesity epidemic [1]. In some countries, up to
one third of the population have NAFLD, although many remain undiagnosed [2, 3]. NAFLD
is defined histologically when >5% of hepatocytes are steatotic in the absence of a secondary
cause, such as excessive alcohol consumption or the use of steatogenic drugs [4]. There is a
spectrum of pathology in NAFLD, ranging from steatosis (fat without hepatocellular injury)
through to non-alcoholic steatohepatitis (NASH; steatosis with hepatocellular injury and lobu-
lar inflammation) and ultimately to cirrhosis [5]. Overall, approximately 40% of patients with
NAFLD develop progressive fibrosis, which results in cirrhosis in 20%, putting patients at risk
of complications, such as hepatocellular carcinoma and liver failure [6–10]. The most impor-
tant prognostic factor in patients with NAFLD is histological stage of liver fibrosis, and sub-
jects with advanced fibrosis have increased risk of liver-related and all-cause mortality [11–
13]. Therefore, a therapy that can reverse liver fibrosis has the potential to reduce risk of liver-
related complications.
Currently, the mainstay of treatment for NAFLD is lifestyle modification, aimed at weight
loss and increased activity, as there is no licenced liver-specific therapy [4, 14]. Weight loss of
greater than 10% of body weight has clearly been shown to be beneficial, with 90% who achieve
this having resolution of steatohepatitis and 45% having regression of fibrosis [15]. Moreover,
all types of exercise can reduce hepatic steatosis and improve metabolic profile [16]. Unfortu-
nately, despite the known beneficial effects of lifestyle modification, many patients fail these
interventions and remain at risk of fibrosis progression.
Liver fibrosis is a complex dynamic process that leads to deposition of matrix proteins, such
as collagens, elastin and proteoglycans, in the liver [17]. During fibrogenesis hepatic stellate
cells become activated in response to pro-inflammatory cytokines, and transform into hepatic
myofibroblasts (HMS), which are the major matrix protein producers in the liver. It is known
that HMS have a local renin-angiotensin system that, when activated, continuously produces
angiotensin II, which acts in an autocrine manner and stimulates fibrogenesis [18, 19]. Impor-
tantly, it has been shown in animal models of NASH and other liver diseases that treatment
with angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers
(ARB) can switch off this profibrogenic state and lead to regression of fibrosis [20–23].
Despite this compelling experimental evidence and the wide availability of well-tolerated,
inexpensive ACEI or ARBs, few human studies have been conducted assessing the potential
anti-fibrotic effects of these drugs in patients with NAFLD [24–26]. The initial aim of this ran-
domised controlled trial was to assess whether treatment with losartan for 96 weeks slowed,
halted or reversed the progression of fibrosis in an adequately powered study in patients with
NASH. However, enrolment to this study was slower than expected and recruitment was
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halted early, when 45 patients were randomised. The revised aims of this study were aligned
with the aim of pilot trials to: (1) to assess the proportion of patients who were eligible for the
study and reasons for non-eligibility to inform the conduct of future clinical trials in this field;
(2) to assess the baseline demographics of the study population and; (3) to describe histological
and biochemical outcomes in the study cohort.
Methods
Study design
This was a double-blind randomised-controlled trial of Losartan 50 mg once a day versus pla-
cebo for 96 weeks in patients with histological evidence of NASH. The study recruited patients
from 11 centres across England between the 6th July 2011 to 19th October 2012. The Sunder-
land Ethics Committee approved the study (REC Reference: 10/H0904/8), and all patients pro-
vided written informed consent.
Inclusion/Exclusion criteria
Adults (aged 18+), with steatohepatitis and fibrosis (NASH Clinical Research Network CRN
[NASH CRN] criteria stage 1–3 [27]), resulting from NAFLD were included in the study. The
main exclusion criteria were: excessive consumption of alcohol (>21 units per week for males
or>14 units per week for females), use of ACEI or ARBs in the previous year, poorly con-
trolled diabetes (Haemoglobin A1C>15%), change in diabetes regimen in the last 3 months,
use of steatogenic medications or drugs that might alter the natural history of NASH (eg pio-
glitazone, vitamin E, GLP-1 analogues etc) or weight loss of>5% body weight within the last 6
months. (Full inclusion/exclusion criteria are shown in S1 File).
Randomisation and outcome measures
Patients were allocated in a 1:1 ratio to Losartan 50 mg once a day or matched placebo for 96
weeks. Randomisation was via a centralised blocked allocation system, and patients, treating
clinicians and those involved in outcome assessment were blinded to treatment group. Since
diabetes is a known major risk factor for progression of fibrosis, patients were stratified by
presence of diabetes (defined according to the 2004 ADA criteria [28] or if they were taking an
oral hypoglycaemic drug or insulin) to avoid imbalances between groups with respect to this
potential confounder. All study participants (both arms) were given standard advice with
regard to diet, exercise and weight maintenance, which was the recommendation to undertake
150 minutes of exercise/per week, combined with a reduction in intake of 500 kcal per day
[29].
The original primary outcome measure for the study was change in histological fibrosis
stage (NASH CRN) from pre-treatment (within 6 months of randomisation) to end-of-treat-
ment (96 weeks). The ’Responder rate’ for placebo and losartan was defined as end-of-treat-
ment liver fibrosis stage less baseline liver fibrosis stage. The secondary outcomes for the study
were to determine:
1. whether Losartan can prevent clinical deterioration in NASH.
2. whether treatment with Losartan affects quality of life in patients with NASH.
3. the association between serum and histological markers of fibrosis in patients with NASH,
over the trial period using the ELF test [30] and other simple non-invasive fibrosis markers
[31].
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Patients were reviewed at baseline, weeks 1, 4, 24, 48, 72, 96 (end of treatment) and 108
(end of study). Investigations conducted at each visit included: weight, Body Mass Index
(BMI), waist circumference, routine biochemical blood tests, Enhanced Liver Fibrosis (ELF)
test, fasting glucose, insulin and lipids and quality of life questionnaires (Chronic Liver Disease
Questionnaire (CLDQ) and SF-36).
Histological assessment
Percutaneous liver biopsies were performed as per unit protocol at the sites. Baseline and end-
of-treatment liver biopsies were centrally assessed by two independent expert hepatopatholo-
gists (ADB and DT) using the NIDDK-sponsored NASH Clinical Research Network (NASH
CRN) criteria [27]. The NAFLD activity score (NAS) was graded from 0 to 8 including scores
for steatosis (0–3), lobular inflammation (0–3) and hepatocellular ballooning (0–2). ‘NASH’
was defined as steatosis with hepatocyte ballooning and lobular inflammation +/- fibrosis.
Fibrosis was staged from F0 to F4, according to NASH CRN [27], on sirius red fast green-
stained sections. Discrepancies between observers’ histological scores were solved by reviewing
the slides and reaching consensus. The trial pathologists were blinded to the baseline or end of
treatment status and treatment assignment.
Sample size calculation and recruitment strategy
Natural history studies suggested that, over a two year period, fibrosis progresses in around
25% of patients with NAFLD [32][33]. There was also regression in approximately 25% of
patients so the mean rate of progression throughout the population is very close to zero.
Pilot data, from a small trial of Losartan in patients with chronic hepatitis C suggested that
the proportion that progress could be brought to nearly 0%, with regression of fibrosis in up
to 50% of patients [34]. A further study giving Losartan for 48 weeks in seven patients with
NASH showed a one point regression in fibrosis stage in four of seven patients with no pro-
gression in the other three [24]. The original sample size calculation is presented in the trial
protocol (see S1 File) and is based on observing a clinically relevant difference in mean fibro-
sis score between Losartan and placebo of 0.42 with assumed standard deviation (SD) of
0.84, 90% power and significance of 0.05 (two tailed test). The original recruitment target
was 170 patients with 96 weeks follow-up, inflated to 214 patients for anticipated attrition.
We estimated that 450 individuals would need to be screened to recruit this number of
patients. Initially, seven units were approached and suggested that they could screen at least
four patients per week, and therefore recruitment was scheduled to take a maximum of six
months between the seven centres. To allow time for centre initiation, 12 months was fac-
tored in for recruitment. Since the start of recruitment, the observed rates of eligibility and
consent were well below expected so the number of sites was expanded to 11 and the recruit-
ment period extended.
Revised objectives
Unfortunately, due to inadequate recruitment to the study funding was withdrawn in October
2012 (at that stage 45 patients had been recruited). It was agreed that patients who were already
recruited could complete the study to help inform the design of future studies. Patients were
given written information about the change in trial objectives and were given the option of
withdrawing at any time. The main revised aims of the study were to assess the:
• Proportion of patients who were eligible for the study and reasons for non-eligibility
• Proportion of eligible patients who agreed to be randomised
RCT of losartan in NASH
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• Baseline demographics
• Level of data completeness
• Measures of central tendency and spread for all study outcomes
• Histological and biochemical outcomes in the study cohort
Analysis of the reasons for slow recruitment
In order to investigate reasons for slow recruitment a detailed retrospective analysis of all
patients who had a liver biopsy for suspected NAFLD from 6 months prior to recruitment
commencing to the end of study (Jan 2011-Sept 2012; 21 months) was performed in Newcas-
tle. Histology results and medical notes were reviewed for all these patients to determine
potential eligibility and reasons for non-eligibility.
As use of an ACEI or ARB in the last year was an exclusion criterion for entry to the trial we
also analysed prescribing rates for the drugs in Newcastle, before and during the trial. This
analysis was conducted using a Primary care research database, which contained comprehen-
sive prescribing information for 149,097 patients over the study period.
Statistical analysis
The analysis was conducted on an intention-to-treat (ITT) basis. The primary analysis of effi-
cacy was based on change in fibrosis score, from baseline to end-of-treatment (96 weeks). The
planned analysis was to assess differences between placebo and intervention groups using anal-
ysis of covariance, with baseline fibrosis score as a covariate along with age, body mass index
and presence of diabetes (factors previously associated with increased risk of progression).
However, in view of inadequate recruitment and the lack of statistical power the analysis plan
was changed to have a descriptive analysis, without conducting formal comparative statistical
tests.
Results
Recruitment
The CONSORT diagram shown in Fig 1 summarises recruitment to the trial and retention
of patients the over the course of the study. Recruitment to the study began in July 2011,
with all seven of the original sites open by November 2011. However, recruitment was
slower than expected (Fig 2) so an additional 4 sites were added between March 2012 and
June 2012. Despite this, recruitment targets were not met nationally and so enrolment was
curtailed, finishing in October 2012. Patients who were already randomised were permitted
to complete the study. Overall, a total of 54 patients were screened (although 1130 had been
‘pre-screened’ and found to be ineligible) for inclusion to the study and 45 were subse-
quently randomised (24 Losartan and 21 placebo). A total of 32 (71%) patients (15 Losartan
and 17 placebo) had the follow up liver biopsy at 96 weeks including one patient who with-
drew from trial treatment but agreed to follow up. Five patients attended the end of treat-
ment visit but did not provide a liver biopsy, 7 patients withdrew completely from the study
(1 patient did not return after visit 3, 2 patients later found to be cirrhotic and was therefore
ineligible, 2 had family planning reasons, 1 diagnosed with coronary artery disease and
commenced on an ACEI, 1 withdrew after reading updated patient information sheet) and
1 patient was lost to follow up.
RCT of losartan in NASH
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Fig 1. Consort diagram of patient recruitment and retention in the study.
https://doi.org/10.1371/journal.pone.0175717.g001
Fig 2. Cumulative recruitment to the study by month.
https://doi.org/10.1371/journal.pone.0175717.g002
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Baseline demographics of the study population
A summary of the baseline demographic and clinical characteristics for the 45 randomised
patients is shown in Table 1. Overall the median age of the cohort was 55 years (range 21–76),
56% were male and 60% were diabetic. All patients in the study were overweight or obese and
the median BMI was 32.9Kg/m2 (range 26.1–45.2). The median stage of liver fibrosis was 2
(IQR 2–3). The median NAS score was 5.5 (IQR 4–6) and 29 (91%) of enrolled patients had
histological evidence of NASH when the slides were reviewed by the study pathologists.
Primary outcome—Change in fibrosis stage between baseline and week
96
A total of 32 (15 Losartan and 17 placebo) out of the 45 (71%) patients who were randomised
had an end of study liver biopsy to assess fibrosis. Overall, one patient (6.7%) treated with
Losartan was a treatment “responder” (lower fibrosis stage at follow up compared with base-
line) and 4 patients (23.5%) in the placebo group were treatment “responders”. However, the
small study size means that no firm conclusion on drug efficacy can be drawn from these
results. Tables 2 and 3 summarises the change in fibrosis stage over the study period in the
Losartan and placebo groups.
Secondary outcomes
The change in biochemical and clinical features between baseline and end of treatment (96
weeks) is shown in Table 4 for the Losartan and placebo treated patients. All parameters were
similar between baseline and end of treatment in both groups, but statistical testing was not
Table 1. Baseline demographic and clinical characteristics, by randomised treatment arm.
Variable Losartan (n = 24) Placebo (n = 21) Total (n = 45)
n Summary n Summary n Summary
Gender n = male (%) 24 13 (54%) 21 12 (57%) 45 25 (56%)
Age (years) 24 58 (25–75) 21 45 (21–76) 45 55 (21–76)
Caucasian ethnicity n (%) 24 21 (88%) 21 19 (90%) 45 40 (89%)
Diabetes n (%) 24 15 (63%) 21 12 (57%) 45 27 (60%)
Weight (kg) 24 85.1 (74.2–121.0) 21 96.7 (61.6–132.5) 45 93.1 (61.6–132.5)
BMI (kg/m2) 23 32.8 (26.1–43.4) 21 34.1 (26.5–45.2) 44 32.9 (26.1–45.2)
Glucose (mmol/l) 24 6.0 (4.4–17.1) 20 6.2 (3.6–15.9) 44 6.0 (3.6–17.1)
ALT (U/L) 24 52.5 (21–136) 21 65 (33–135) 45 59 (21–136)
AST (U/L) 21 35 (14–102) 18 46 (30–70) 39 43 (14–102)
Gamma GT (U/L) 24 70 (18–355) 21 62 (23–256) 45 64 (18–355)
ALP (U/L) 24 89.5 (44–173) 21 72 (49–116) 45 84 (44–173)
Creatinine (μmol/l) 24 75.5 (48–105) 21 72 (5–97) 45 74 (5–105)
Triglyceride (mmol/l) 23 1.7 (0.9–7.9) 19 2.0 (0.4–4.4) 42 1.9 (0.4–7.9)
HDL Cholesterol (mmol/l) 22 1.1 (0.7–2.8) 20 1.1 (0.8–3.5) 42 1.1 (0.7–3.5)
Total Cholesterol (mmol/l) 23 4.3 (2.1–7.5) 20 4.6 (1.0–6.5) 43 4.3 (1–7.5)
LDL Cholesterol (mmol/l) 19 2.5 (0.8–3.8) 18 3.2 (1.2–4.4) 37 3 (0.8–4.4)
Platelets (x109/L) 23 224 (137–360) 21 224 (158–404) 44 224 (137–404)
ELF test 23 8.8 (6.5–11.8) 19 8.0 (6.4–10.3) 42 8.3 (6.4–11.8)
Median and (Range) AST, aspartame aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Gamma GT, gamma glutamyl
transferase; ELF, Enhanced liver fibrosis test; HDL, high density lipoprotein; LDL, low density lipoprotein; BP, blood pressure.
https://doi.org/10.1371/journal.pone.0175717.t001
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preformed due to the small sample size. Overall, there was no change in NAS over the treat-
ment period in patients treated with losartan (median change in NAS 0 [range -3 to 3]),
whereas there was a reduction in NAS in the placebo treated patients (median change in
NAS -1 [range -4 to 1]. Overall quality of life, as measured by the CLDQ, remained largely
unchanged in both groups over the trial period (Fig 3).
Table 2. Summary statistics for liver fibrosis assessed by the NASH CRN criteria [27] at baseline and 96 weeks by trial arm.
Variable Losartan Placebo
Fibrosis stage Baseline n = 15 96 weeks n = 15 Baseline n = 17 96 weeks n = 17
0 1 (6.7%) 1 (6.7%) 1 (5.9%) 1 (5.9%)
1 3 (20%) 2 (13.3%) 0 (1%) 2 (11.8%)
2 6 (40%) 7 (46.7%) 8 (47.1%) 6 (35.3%)
3 4 (26.7%) 4 (26.7%) 7 (41.2%) 6 (35.3%)
4 1 (6.7%) 1 (6.7%) 1 (5.9%) 2 (11.8%)
Mean (sd) 2.07 (1.03) 2.13 (0.99) 2.41 (0.87) 2.35 (1.06)
Median (IQR) 2 (1–3) 2 (2–3) 2 (2–3) 2 (2–3)
https://doi.org/10.1371/journal.pone.0175717.t002
Table 3. Change in fibrosis stage from baseline to 96 weeks.
Variable Losartan n = 15 Placebo n = 17
Change in fibrosis stage from baseline to 96 weeks -1 n = 1 (6.7%)
0 n = 12 (80%)
1 n = 2 (13.3%)
-1 n = 4 (23.5%)
0 n = 10 (58.8%)
1 n = 3 (17.6%)
Median change in fibrosis stage from baseline to 96 weeks (IQR) 0 (0–0) 0 (0–0)
https://doi.org/10.1371/journal.pone.0175717.t003
Table 4. Clinical characteristics at baseline and 96 weeks in the losartan and placebo treated patients.
Losartan Placebo
Baseline (N = 24) 96 weeks (N = 18) Baseline (N = 21) 96 weeks (N = 19)
Variable n Median (range) n Median (range) n Median (range) n Median (range)
Weight (kg) 24 85.1 (74.2–121.0) 18 86.6 (73.5–113.9) 21 96.7 (61.6–132.5) 19 94.2 (60.3–129.7)
Waist circumference (cm) 24 105.9 (96.0–126.0) 18 108.0 (96.0–129.0) 21 111.4 (88.0–136.0) 19 112.5 (93.0–131.0)
AST (U/L) 21 35 (14–102) 17 31 (2–70) 18 46 (30–70) 16 36 (17–110)
ALT (U/L) 24 52.5 (21–136) 18 32.5 (7–80) 21 65 (33–135) 18 52 (18–133)
ALP (U/L) 24 89.5 (44–173) 18 89.5 (37–191) 21 72 (49–116) 17 79 (46–106)
Gamma GT (U/L) 24 70 (18–355) 18 55.5 (22–371) 21 62 (23–256) 17 48 (16–342)
ELF test 23 8.8 (6.5–11.8) 18 9.4 (7.9–11.0) 19 8.0 (6.4–10.3) 15 9.1 (7.3–10.8)
Creatinine (umol/L) 24 75.5 (48–105) 18 73.5 (43–106) 21 72 (5–97) 17 68 (52–94)
Triglyceride (mmol/L) 23 1.7 (0.9–7.9) 17 2 (0.8–6.5) 19 2.0 (0.4–4.4) 18 1.7 (0.9–4.4)
HDL Cholesterol (mmol/L) 22 1.1 (0.7–2.8) 16 1.0 (0.8–1.9) 20 1.1 (0.8–3.5) 16 1.1 (0.8–1.8)
Total Cholesterol (mmol/L) 23 4.3 (2.1–7.5) 16 4.0 (2.2–7.6) 20 4.6 (1.0–6.5) 18 4.4 (2.7–6.5)
LDL Cholesterol (mmol/L) 19 2.5 (0.8–3.8) 13 1.9 (0.5–4.2) 18 3.2 (1.2–4.4) 15 2.6 (1.0–3.8)
Glucose (mmol/L) 24 6.0 (4.4–17.1) 18 8.1 (4.8–19.7) 20 6.2 (3.6–15.9) 18 6.7 (4.3–15.8)
Systolic BP 24 133.5 (109–165) 18 129 (106–152) 21 127 (115–180) 19 125 (111–175)
Diastolic BP 24 78.5 (67–95) 18 74 (63–96) 21 81 (70–100) 19 80 (65–96)
Platelets (x10^9/L) 23 224 (137–360) 18 224 (135–362) 21 224 (158–404) 19 209 (155–349)
Median (range). AST, aspartame aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Gamma GT, gamma glutamyl transferase;
ELF, Enhanced liver fibrosis test; HDL, high density lipoprotein; LDL, low density lipoprotein; BP, blood pressure.
https://doi.org/10.1371/journal.pone.0175717.t004
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Due to the small sample size and the relatively few patients whose fibrosis stage changed
over the study period, an analysis of the association between histological markers serum of
fibrosis over the study period was not performed.
Adverse Events (AEs)
Overall, there were 100 AEs in the Losartan treated patients and 101 in the placebo group
(Table 5). There were 3 serious adverse events (SAEs) in patients who received Losartan, but
all were thought not related to treatment (1 fracture metacarpal, 1 dislocation of metacarpal
and 1 epistaxis). There was 1 SAE in the placebo group, though not related (1 fall and rib
fracture).
Reasons for the inadequate recruitment
Overall, a total of 1130 patients were “pre-screened” in the sites for the study, and from this
only 54 were formally screened for the study. The major reason for low recruitment rates
appeared to be the widespread pre-existing use of ACEI or ARBs in NAFLD patients who were
otherwise eligible for the study. A detailed analysis of eligibility for the study was conducted in
patients from Newcastle and is shown in Fig 4. Overall, between Jan 2011 and Sept 2012 (21
months) 153 patients had a liver biopsy to diagnose or stage NAFLD. Of these, 82 (54%) had
non-cirrhotic NASH, 38 (25%) were potentially eligible for the study and 20 (13%) were ulti-
mately enrolled. Thirty-two (39%) of the patients with non-cirrhotic NASH were taking and
ACEI or and ARB and 12 (15%) were taking other prohibited medication, making them ineli-
gible for the study.
Fig 3. Quality of life as measured by the Chronic Liver Disease Questionnaire (CDLQ) during the
study period (from baseline to end of treatment [week 96]). (AS = abdominal symptoms; FS = Fatigue
symptoms; SS = systemic symptoms; AC = Activity; EF = Emotional functioning; WO = worry).
https://doi.org/10.1371/journal.pone.0175717.g003
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Table 5. Reported adverse events in the study population (ITT analysis).
Related to treatment Severity Losartan
n(%)
Placebo
N(%)
Not related Mild 43 (51.19%) 56 (76.71%)
Moderate 34 (40.48%) 16 (21.92%)
Severe 7 (8.33%) 0 (0%)
Missing 0 (0%) 1 (1.37%)
Total 84 73
Possibly related Mild 9 (60%) 24 (92.31%)
Moderate 6 (40%) 1 (3.85%)
Severe 0 (0%) 1 (3.85%)
Missing 0 (0%) 0 (0%)
Total 15 26
Probably related Mild 1 (100%) 0 (0%)
Moderate 0 (0%) 0 (0%)
Severe 0 (0%) 0 (0%)
Missing 0 (0%) 0 (0%)
Total 1 0
Missing Mild 0 (0%) 2 (100%)
Moderate 0 (0%) 0 (0%)
Severe 0 (0%) 0 (0%)
Missing 0 (0%) 0 (0%)
Total 0 2
Arm Total 100 101
https://doi.org/10.1371/journal.pone.0175717.t005
Fig 4. An overview of a detailed analysis of eligibility for all patients who had a liver biopsy to
diagnose or stage NAFLD in Newcastle between Jan 2011 and Sept 2012 (21 months).
https://doi.org/10.1371/journal.pone.0175717.g004
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Over the time from conception of the study (2007–8), to obtaining funding (2009), to
recruitment beginning (2011) there was a change in the management of hypertension in the
UK, with ACEI or ARBs being recommended first line by the National Institute of Health and
Care Excellence (NICE) in August 2011 [35]. Fig 5 shows the increasing number of patients
prescribed ACEI or ARBs in a Newcastle Primary care cohort, which includes prescribing data
for 149,097 patients, between 2007 and 2012. There was a more than doubling of patients pre-
scribed ACEI or ARBs in Newcastle from the time of conception of the study to recruitment
commencing, which may have had an impact by reducing the pool of eligible patients for the
study.
Other reasons cited by the participating centres for low recruitment rates was the increasing
use of transient elastography to stage liver fibrosis in patients with NAFLD, which reduced
the proportion of patients being diagnosed with NASH histologically. In addition, there were
competing trials of other agents that were recruiting patients with NASH in the UK at that
time.
Discussion
Non-alcoholic fatty liver disease is now the most common chronic liver disease in many coun-
tries across the world [1], and is the second most common indication for liver transplantation
in the USA, after hepatitis C [36]. Despite its high prevalence, there are currently no specific
licensed therapies to treat NAFLD, and lifestyle modification and treatment of co-existent fea-
tures of the metabolic syndrome are the mainstay of its management [14]. In NAFLD the most
important long-term prognostic factor is stage of liver fibrosis, and patients with advanced
(stage 3–4) fibrosis have increased rates of liver-related morbidity and mortality, as well as
Fig 5. Number of patients prescribed Angiotensin Converting Enzyme Inhibitors (ACEI) or
Angiotensin Receptor Blockers (ARB) in the Newcastle Primary care cohort (n = 149,097) from the
time of conception (2007–8), to obtaining funding (2009), to recruitment beginning (2011).
https://doi.org/10.1371/journal.pone.0175717.g005
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increased all-cause mortality [11–13]. Therefore, anti-fibrotic drugs are an attractive therapeu-
tic option as they could have the potential to reverse liver fibrosis and improve long-term
prognosis.
There is a wealth of data demonstrating the antifibrotic effects of ACEI and ARBs in experi-
mental and animal models of liver fibrosis [20–23]. However, to date few studies have been
conducted in humans, particularly in patients with NASH (see below) [24][25]. The original
aim of the present study was to determine whether 96 weeks of treatment with losartan slowed,
halted or reversed fibrosis in a sufficiently powered randomised controlled trial of patients
with NASH. However, recruitment was slower than expected and the trial was halted early
after only 45 patients were randomised, and as a result had insufficient power to answer this
question. Only one of the 15 (6.7%) Losartan treated patients with paired biopsies was a “treat-
ment responder” (less fibrosis on the follow up biopsy compared with the baseline biopsy)
compared with 4 of the 17 (23.5%) patients in the placebo group, suggesting no benefit from
Losartan in this small cohort.
A major reason for the inadequate recruitment to the study was the increasing use of ACEI
or ARBs in the UK, particularly with the 2011 National Institute of health and Care Excellence
(NICE) guidelines recommending ACEI or ARBs first line for hypertension [35]. This was not
predicted during the conception of the study. Over the period from conception of the study
(2007/8) to the trial being conducted (2011/12), data from the Newcastle Primary care research
cohort (n = 147,097) suggested that there was a more than 2-fold increase in the number of
patients were prescribed ACEIs and ARBs in the Newcastle region, which supports this
hypothesis. Moreover, we conducted a detailed examination of eligibility for the study in all
the patients who had a liver biopsy for suspected NAFLD in Newcastle over the recruitment
period and found that 39% of the patients with non-cirrhotic NASH (potentially eligible) were
already taking an ACEI or ARB. ACEI and ARBs are also widely prescribed for hypertension
in other countries. In one study from the USA 186 of 290 (64%) hypertensive patients with
NASH were treated with ACEI or ARBs. [37]. ACEI and ARB are also widely prescribed in for
reno-protection in individuals with diabetes. Conducting future trials of these drugs in adults
with NASH is likely to be difficult as many of the potential recruits will already be prescribed
ACEI or ARBs. Conducting a trial of ACEI or ARBs in children with NASH may be an option
to determine their efficacy, particularly as their long term safety has been well demonstrated.
As well as the low recruitment rate in this study, the dropout rate was higher than expected
(29%). The requirement for a follow up liver biopsy is likely to be a factor contributing to this
high rate. Another potential contributing factor is that when the study participants were
advised of the change in trial protocol that they may have felt that is was not worth continuing
in the study.
The primary outcome measure for this study was the change in fibrosis stage between base-
line and 96 weeks. Overall, including patients from both groups, there was no change in fibro-
sis stage over the study period, with 5 patients having improvement by 1 fibrosis stage, 5
having progression of 1 fibrosis stage and the others remaining stable. Our observed rate of
fibrosis progression was less than had been expected based on available natural history data at
the time. Since this study was designed, other studies have more clearly defined the natural his-
tory of fibrosis in NAFLD. These show that overall approximately 40% of patients have fibrosis
progression and 20% will have fibrosis regression over longer follow up periods (median fol-
low up 3.7–6.6 years) [8, 9] In general, fibrosis progression is slow in NASH with patients
progressing by one fibrosis stage every 7.1 years [6]. It is likely that studies may need to be con-
ducted over longer periods, such as 5 years, to see benefit from some anti-fibrotics.
To date, most trials have used the NASH CRN system as the endpoint for assessment of
fibrosis, which stages fibrosis semi-quantitatively from 0 to 4 [27]. However, this method is
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relatively insensitive for subtle changes in fibrosis and has the potential to miss minor changes
in fibrosis that could be clinically significant over the longer term. Assessment of collagen pro-
portionate area using image analysis of liver biopsy specimens might offer a more sensitive
method to assess change in liver fibrosis in future studies of antifibrotics [38]. There is also
need for accurate biomarkers that can give an early indication of an anti-fibrotic effect, analo-
gous to the “rapid viral response” in patients with chronic hepatitis C treated with interferon
and ribavirin [39]. One of the secondary outcomes of this study was to determine whether
serum fibrosis biomarkers could predict changes in fibrosis over the study period. However,
this analysis was not conducted due to the small sample size.
A few other studies have suggested benefit from treatment with ARBs in patients with
NASH. Firstly, Yokohama et al showed that 4 of 7 hypertensive patients treated with Losartan
for 48 weeks had improvement in liver fibrosis [24]. Subsequently, a larger randomized trial
comparing Telmisartan with Valsartan for 20 months in 54 hypertensive patients with NASH
found a significant reduction in fibrosis stage and NAS in the patients treated with Telimsar-
tan, but no significant change in these parameters in the Valsartan treated patients [25]. There
were significant improvements in steatosis, serum transaminases and insulin sensitivity in
both groups over the study period. Further support for the potential anti-fibrotic effect of
drugs blocking renin-angiotensin system (RAS) comes from a cross sectional study of 290
hypertensive patients with NASH, which found that patients treated with ACEI or ARBs had
less advanced fibrosis than patients treated with other anti-hypertensives [37]. However, in
contrast, a well-conducted randomized open label trial from the USA found that Losartan
when combined with rosiglitazone was no more effective than rosiglitazone alone or rosiglita-
zone combined with metformin [26]. It therefore remains unknown whether ARBs have an
anti-fibrotic effect in patients with NASH.
Experimental studies have suggested a number of mechanisms whereby drugs that block the
RAS could have a beneficial effect in patients with NASH and other liver diseases (reviewed in
[20, 40]). Overall, in models of liver injury, there is upregulation of RAS activity in areas of active
fibrosis [41]. Angiotensin II (Ang II), the physiologically active product of the RAS, activates
hepatic stellate cells promoting their differentiation into HMS and inducing a fibrogenic state.
HMS themselves produce Ang II, which activates the angiotensin 1 receptor (AT1R) and pro-
motes the survival of the HMS by upregulating anti-apoptosis genes via NF-κB activation. [18,
42] Therefore, blocking this pathway with ACEI or ARBs could promote HMS apoptosis and
lead to regression of fibrosis. As well as being potentially anti-fibrotic, drugs that block the RAS
may also have beneficial metabolic effects in patients with NAFLD. Previous studies have shown
that activation of the RAS may impair insulin signalling, contributing to insulin resistance,
which is a key pathophysiological mechanism in NAFLD [43]. Interestingly treatment with
ACEI or ARBs can improve insulin sensitivity, and a large meta-analysis found there was a 20%
reduction in new onset diabetes in patients treated with ACEI or ARBs [44]. This improvement
in insulin sensitivity could have a secondary effect of improving steatosis and steatohepatitis [25].
The present study also highlights that it can take significant amount of time from submis-
sion of an application for grant funding to support an investigator-led study, before funding is
awarded and enrolment commences. During this time, routine clinical practice may change,
rendering the study moot or hampering the ability to recruit patients into the study. For future
studies we therefore recommend that, when there is a delay of more than 6-months between
submission of the initial funding application and the trial commencing, feasibility is reassessed
and an initial pilot study is conducted to establish recruitment feasibility prior to expanding
the trial to full recruitment.
In conclusion, the aim of this double-blind randomised-controlled trial was to determine
whether treatment with Losartan had an anti-fibrotic effect in patients with NASH. However,
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the trial under recruited due to the widespread use of ACEI and ARBs in the study population
and as a result the study was unable to determine whether losartan has anti-fibrotic effects
in the liver. Given the widespread use of ACEI and ARBs for hypertension in patients with
NAFLD, conducting a definitive placebo controlled trial of these drugs will be a challenge.
As ARBs are effective antihypertensive and may also improve insulin sensitivity, they seem a
good choice to treat hypertension in patients with NAFLD, even if an anti-fibrotic effect is not
proven.
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